ADAPY
ADAPY clinical trials: Adaptimmune Therapeutics PLC
Every trial on ClinicalTrials.gov where Adaptimmune Therapeutics PLC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 13
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADAPY on the catalyst calendar · ADAPY registry changes
- Primary completion Jul 7, 2021ActualPhase 1NCT03132792AFPᶜ³³²T in Advanced HCCAdaptimmune · Hepatocellular CancerCompletedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2019ActualPhase 1NCT02989064MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersAdaptimmune · Urothelial CarcinomaCompletedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2020ActualPhase 1NCT02592577MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLCAdaptimmune · Non-Small Cell Lung CancerCompletedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2024ActualNo phase registeredNCT02636855Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility DeterminationAdaptimmune · Solid and Hematological MalignanciesCompletedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 8, 2023ActualPhase 1NCT06048705Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and...Adaptimmune · NeoplasmsTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2022ActualPhase 1NCT05943990Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaAdaptimmune · NeoplasmsTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 8, 2023ActualPhase 1NCT04526509Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive...Adaptimmune · NeoplasmsTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 9, 2023ActualPhase 2NCT04752358ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)Adaptimmune · Esophageal CancerTerminatedADAPYLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2021Sponsor estimatePhase 2NCT04408898SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck CancerAdaptimmune · Head and Neck CancerWithdrawnADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 24, 2018ActualNo phase registeredNCT03391791Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell ReceptorsAdaptimmune · Solid and Hematological MalignanciesTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2017ActualPhase 1/Phase 2NCT01567891CT Antigen TCR-redirected T Cells for Ovarian Cancer.Adaptimmune · Ovarian CancerCompletedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2014ActualPhase 1/Phase 2NCT01892293CT Antigen TCR-Engineered T Cells for MyelomaAdaptimmune · Multiple MyelomaTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2016ActualPhase 1/Phase 2NCT01350401Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic MelanomaAdaptimmune · MelanomaTerminatedADAPYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2027Sponsor estimatePhase 1NCT06204991To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic MelanomaInge Marie Svane · Melanoma Stage IIIRecruitingADAPYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualPhase 1NCT00991224Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene TherapyUniversity of Pennsylvania · HIV InfectionsCompletedADAPYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner